Complement function in mAb-mediated cancer immunotherapy.

Abstract Complement activation by mAbs can cause direct tumor cell lysis or enhance antibody-dependent cell-mediated cytotoxicity. However, tumor cells are protected from complement-mediated injury by membrane-bound complement regulatory proteins (mCRP) that are often expressed at elevated levels on tumor cells. Recent studies indicate that blocking or overwhelming the function of tumor cell mCRP might substantially improve the efficacy of monoclonal antibody (mAb) immunotherapy. In addition, the use of β-glucan as an adjuvant for mAb immunotherapy enables iC3b deposited on tumor cells by mAbs to activate complement receptor 3 (CR3) on effector cells, thus inducing CR3-dependent cellular cytotoxicity. These strategies provide novel cell-mediated mechanisms of tumor cytotoxicity that are additive to all other mAb effector mechanisms.

[1]  O. Spiller,et al.  Human and rodent decay‐accelerating factors (CD55) are not species restricted in their complement‐inhibiting activities , 2000, Immunology.

[2]  S. Meri,et al.  Immune evasion of tumor cells using membrane-bound complement regulatory proteins. , 1999, Immunology today.

[3]  A. Kennedy,et al.  An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. , 2003, Blood.

[4]  滝沢 壽男.  Complement inhibitor of rat cell membrane resembling mouse Crry/p65 , 1995 .

[5]  A. Andoh,et al.  Interleukin 4 acts as an inducer of decay-accelerating factor gene expression in human intestinal epithelial cells. , 1996, Gastroenterology.

[6]  A. Vickers,et al.  Orally administered β-glucans enhance anti-tumor effects of monoclonal antibodies , 2002, Cancer Immunology, Immunotherapy.

[7]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[8]  Z. Fishelson,et al.  Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. , 2003, Molecular immunology.

[9]  N. Fedarko,et al.  Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  N. Cheung,et al.  CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma. , 2000, Cancer research.

[11]  T. Mayadas,et al.  The b-Glucan-Binding Lectin Site of Mouse CR 3 ( CD 11 b / CD 18 ) and Its Function in Generating a Primed State of the Receptor That Mediates Cytotoxic Activation in Response to iC 3 b-Opsonized Target Cells 1 , 1999 .

[12]  L. Presta,et al.  Engineered Antibodies with Increased Activity to Recruit Complement , 2001, The Journal of Immunology.

[13]  J. Uhr,et al.  Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  D. Goldenberg,et al.  Interferon-gamma upregulates MUC1 expression in haematopoietic and epithelial cancer cell lines, an effect associated with MUC1 mRNA induction. , 2003, European journal of cancer.

[15]  G. D. Ross,et al.  Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein. , 2000, Critical reviews in immunology.

[16]  H. Juhl,et al.  Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17‐1A , 1997, Journal of surgical oncology.

[17]  T. Seya,et al.  Distribution of C3-step regulatory proteins of the complement system, CD35 (CR1), CD46 (MCP), and CD55 (DAF), in hematological malignancies. , 1994, Leukemia & lymphoma.

[18]  V. Hu,et al.  Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9. , 1985, Journal of immunology.

[19]  Valeria Grieco,et al.  Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo 1 , 2003, The Journal of Immunology.

[20]  N. Cheung,et al.  Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  M. Daha,et al.  Cytokines Affect Resistance of Human Renal Tumour Cells to Complement‐Mediated Injury , 2003, Scandinavian journal of immunology.

[22]  B. Kroesen,et al.  Tumor‐targeted immune complex formation: Effects on myeloid cell activation and tumor‐directed immune cell migration , 2002, International journal of cancer.

[23]  G. Ostroff,et al.  Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. , 2003, Cancer research.

[24]  H. Juhl,et al.  Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells. , 1997, Immunobiology.

[25]  M. Glennie,et al.  The mechanisms of action of rituximab in the elimination of tumor cells. , 2003, Seminars in oncology.

[26]  Chen,et al.  Protection of human breast cancer cells from complement‐mediated lysis by expression of heterologous CD59 , 1999, Clinical and experimental immunology.

[27]  T. Mayadas,et al.  b-Glucan , a “ Specific ” Biologic Response Modifier That Uses Antibodies to Target Tumors for Cytotoxic Recognition by Leukocyte Complement Receptor Type 3 ( CD 11 b / CD 18 ) 1 , 1999 .

[28]  T. Seya,et al.  Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies , 1992, British journal of haematology.

[29]  M. Cragg,et al.  Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. , 2004, Blood.

[30]  M. Trikha,et al.  Monoclonal antibodies as therapeutics in oncology. , 2002, Current opinion in biotechnology.

[31]  B. Morgan,et al.  Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59 , 1997, Clinical and experimental immunology.

[32]  H. Juhl,et al.  Complement killing of human neuroblastoma cells: a cytotoxic monoclonal antibody and its F(ab')2-cobra venom factor conjugate are equally cytotoxic. , 1990, Molecular immunology.

[33]  P. Carter,et al.  Improving the efficacy of antibody-based cancer therapies , 2001, Nature Reviews Cancer.

[34]  G. Fleuren,et al.  Enhancement of the complement activating capacity of 17‐1A mAb to overcome the effect of membrane‐bound complement regulatory proteins on colorectal carcinoma , 2002, European journal of immunology.

[35]  C. Schmitt,et al.  Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours. , 1999, European journal of cancer.

[36]  Z. Fishelson,et al.  Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2. , 1999, Immunopharmacology.

[37]  M. Young,et al.  Factor H Binding to Bone Sialoprotein and Osteopontin Enables Tumor Cell Evasion of Complement-mediated Attack* , 2000, The Journal of Biological Chemistry.

[38]  J. Ravetch,et al.  Divergent roles for Fc receptors and complement in vivo. , 1998, Annual review of immunology.

[39]  L. Chung,et al.  Targeting of cancer cells with monoclonal antibodies specific for C3b(i) , 2000, Cancer Immunology, Immunotherapy.

[40]  W. Weng,et al.  Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  G. Salles,et al.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.

[42]  Z. Fishelson,et al.  Targeting of complement to tumor cells by heteroconjugates composed of antibodies and of the complement component C3b. , 1989, Journal of immunology.

[43]  L. D'Cruz,et al.  Expression of factor I‐resistant mutants of the human complement component C3 in heterologous systems , 1998, Xenotransplantation.

[44]  R. Marconi,et al.  Analysis of the Ability of Spirochete Species Associated with Relapsing Fever, Avian Borreliosis, and Epizootic Bovine Abortion To Bind Factor H and Cleave C3b , 2003, Journal of Clinical Microbiology.

[45]  N. Cheung,et al.  Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. , 1988, The Journal of clinical investigation.

[46]  G. Fleuren,et al.  A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement. , 1998, Journal of immunology.

[47]  M. Glennie,et al.  Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. , 1995, Journal of immunology.

[48]  D. Buckley,et al.  Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients , 2003, Cancer Immunology, Immunotherapy.

[49]  S. Bernasconi,et al.  Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. , 2000, Blood.

[50]  L. Baranyi,et al.  Cell-surface bound complement regulatory activity is necessary for the in vivo survival of KDH-8 rat hepatoma. , 1994, Immunology.

[51]  V. Zurawski,et al.  New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. , 1994, Cancer research.

[52]  A. Dalmasso,et al.  Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). , 1996, The American journal of pathology.

[53]  V. Vetvicka,et al.  Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. , 1996, The Journal of clinical investigation.

[54]  G. Fleuren,et al.  The Inhibitory Effect of CD46, CD55, and CD59 on Complement Activation After Immunotherapeutic Treatment of Cervical Carcinoma Cells with Monoclonal Antibodies or Bispecific Monoclonal Antibodies , 2002, Laboratory Investigation.

[55]  J. Monson,et al.  m17-1A-, c17-1A- and cSF25-mediated antibody-dependent cell-mediated cytotoxicity in patients with advanced cancer. , 1994, British Journal of Cancer.

[56]  H. Juhl,et al.  Title>Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells , 1997 .

[57]  N. Cheung,et al.  Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. , 1998, Cancer research.

[58]  M. Urashima,et al.  Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. , 1999, Blood.

[59]  J. Byrd,et al.  Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  M. Sliwkowski,et al.  Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). , 1999, Seminars in oncology.

[61]  A. Frey,et al.  A tumor-expressed inhibitor of the early but not late complement lytic pathway enhances tumor growth in a rat model of human breast cancer. , 2002, Cancer research.

[62]  T. Barbui,et al.  CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. , 2001, Blood.

[63]  N. Cheung,et al.  Oral ( 1 3 3 ) , ( 1 3 4 )-- D-Glucan Synergizes with Antiganglioside GD 2 Monoclonal Antibody 3 F 8 in the Therapy of Neuroblastoma 1 , 2002 .

[64]  M. Daha,et al.  A Possible Role of CD46 for the Protection In Vivo of Human Renal Tumor Cells from Complement-Mediated Damage , 2000, Laboratory Investigation.